27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Biogen Inc (NASDAQ: BIIB) is down 3 percent on Friday after commentary from Cowen. Analyst Eric Schmidt suggested investors not play the company's upcoming AAIC data reveal centered on Aducanumab, scheduled for July 22, due to a lack of conviction.
It didn't take long for RBC's trading desk to respond.
In a note circulating among traders, the firm said it believes "the primary reason for the action is due to a competitor report that relates to a bit more cautious/balanced tone on upcoming Alzheimer's data," though Cowen was not specifically mentioned.
RBC admitted new placebo data could change the overall outlook for Biogen's drug, but added it's not a new idea. "In addition, the company hasn't presented in public in almost two months so there haven't been any comments by the company," the firm added.
Expectations
It's thought the market is expecting a 40 to 50 percent chance of success for Aducanumab. Schmidt's note said he sees a 60 to 70 percent range if AAIC data impresses investors, and a 20 percent mark if it whiffs. He said these numbers in turn give Biogen stock a possibility of swinging $50 in either direction.
RBC puts the probability of Aducanumab success at 65 percent, but warns, "we won't know that for a while as Phase III is just starting." In its eyes, Biogen could move $38 to $39 in either direction after the data release -- a 10 percent swing.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!